Royalty Pharma PLC: “I like it, and I’m going to stick with it. It’s not big, but it’s not bad.”
Tellurian Inc: “It’s at $2, and stocks stop at $0. They don’t go to minus $2. So, I’m okay with Tellurian.”
Zoetis Inc: “I think the stock is now undervalued. … It’s a buy.”
Ryan Mckeever | E+ | Getty Images Move over, Sephora kids. While younger generations have been buying beauty products in droves, data shows that a different generation holds more spending power: Generation X. Often dubbed the “forgotten generation,” Gen X spans those born between 1965 and 1980, according to Pew Research Center. Sandwiched between baby […]
Read More
FILE PHOTO: Psilocybin or “magic mushrooms” are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That […]
Read More
A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. New York’s proposed tax on second homes worth more than $5 million is likely to spark costly legal battles over how to value […]
Read More
